Standard International Trade Classification
U.S. imports of Other Hormone Medicaments (Non-Insulin, Non-Adrenal Cortical), Dosage Form or Retail Packings (SITC 54229) totaled $931.0M in August 2026, imported from 34 countries.
Importers of Other Hormone Medicaments (Non-Insulin, Non-Adrenal Cortical), Dosage Form or Retail Packings paid $1.3M in duties in August 2026, an average duty rate of 0.14% — duty actually collected as a share of the imports that cleared customs, not the published tariff schedule. Other Hormone Medicaments (Non-Insulin, Non-Adrenal Cortical), Dosage Form or Retail Packings imports of $931.0M in August 2026 ran 29% above the year-to-date monthly average of $720.1M.
Last updated: August 2026 dataFinished medicaments containing hormones, hormone derivatives, and steroids used as hormones — excluding insulin and adrenal cortical hormones — in dosage or retail form cover a commercially diverse range of products including sex hormones, thyroid hormones, growth hormones, and synthetic analogs used in endocrinology, oncology, and reproductive medicine. FDA admissibility review applies, and certain anabolic steroid products in this category also require DEA import authorization as Schedule III controlled substances. The NES designation makes this a residual heading, so classification accuracy depends on ruling out insulin and adrenal cortical hormone content first. Importers of biosimilar growth hormones should confirm FDA licensure status before shipment.
AI-written summary of the official U.S. Census Bureau trade figures on this page — verify before relying on it.
755 import shipments a month
Combination hormone products present a genuine classification challenge. The applicable heading depends on which active ingredient is considered primary under the relevant classification rules, and the adrenal cortical hormone heading may take precedence if that component drives the product's therapeutic use. This is an edge case where a licensed customs broker or trade attorney with pharmaceutical classification experience should be consulted before entry.
Recombinant human growth hormone (somatropin) is regulated as a biologic under the Public Health Service Act, so the foreign manufacturer must hold an FDA biologics license or have an approved biosimilar application. Additionally, growth hormone is a controlled substance under the Anabolic Steroid Control Act in certain contexts, and its importation for non-approved uses is restricted. Importers should confirm both FDA licensure and any applicable DEA requirements before shipment.
Basic heading 3 of 465 in section 5
Basic heading 54229 · $931.0M of $27.5B
Trade Directory
List your company and tag the 6-digit products you trade, so the companies trading them can find you. Be the first supplier listed.
Imports · August 2026
origin
China and Ireland together supply 71% of it.
customs district
Census does not publish district detail for this classification system.
destination
Census does not publish state detail for this classification system.
entry
Census does not publish port detail for this classification system.
ImportsExports
Imports
$931.0MYoY · free account
Exports
$623.3MYoY · free account
12-mo low · imports
Low · free accountOver the twelve months to August 2026, the U.S. imported $7.3B of Other Hormone Medicaments (Non-Insulin, Non-Adrenal Cortical), Dosage Form or Retail Packings and exported $5.8B.
Through August 2026. Source: U.S. Census Bureau.